Frontlight ResearchEarly access
WithdrawnPhase 1
ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML
Key facts
- Who runs it
- Elucida Oncology
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- 7 Jun 2024
- Ended
- 7 Jun 2024
- Type of study
- Interventional
- Treatments tested
- ELU001
- Record updated
- 7 August 2024
- Why it stopped
- Lack of Funding - no safety issue with Drug; Company Permanently Closed
Who can take part
- Age
- 1 month to 9 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Patients must meet the following criteria to enroll in this study:
- Infants (>1 month) and children (≤9 years) at time of enrollment
- Relapsed or refractory CBFA2T3::GLIS2 positive AML
- CNS1 or CNS2 during screening
- Performance Status: Lansky ≥ 50
- Adequate Organ Function including liver, kidney, and heart
Who cannot take part
- Prior treatment with folate receptor-targeting anti-cancer agent(s) ≤ 21 days (or 2 half-lives must have elapsed before enrollment, whichever is longer), or received investigational anti-cancer treatment ≤ 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, prior to starting study drug, whichever is shorter
- CNS3 Disease
- AML associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom syndrome, Kostmann syndrome or Diamond-Blackfan anemia, or bone marrow failure associated with inherited syndromes
- Clinically significant active or chronic corneal disorder, particularly corneal epitheliopathy or any eye disorder that may predispose patient to this condition, or unable to comply with an age-appropriate ophthalmologic examination
- Patients who meet any of the following are not eligible to enroll in this study:
- Acute promyelocytic leukemia
About the trial
What the trial wants to find out
This research study was planned to focus on a rare type of acute myeloid leukemia (with the subtype CBFA2T3::GLIS2 that overexpresses folate receptor alpha (FRα) (a protein on the surface of leukemia cells)) that has relapsed or is refractory. Relapse means the cancer has come back after treatment. Refractory means the cancer does not respond to treatment.
The group in the trial
- ELU001Treatment being tested
Dose Escalation: Escalating doses of ELU001
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Dose Escalation Study to Evaluate the Safety and Tolerability of ELU001 in Pediatric Patients Who Have Relapsed and/or Refractory CBFA2T3::GLIS2 Positive Acute Myeloid Leukemia
- Record updated
- 7 August 2024